Genmab — Maj 2018
-
-
Sjovt nok umiddelbart efter SEB opjusterede kursmålet med 10 procent. Men det er nok bare et tilfælde....
-
God morgen.
-
MS partner Novartis showing its strength again there with another approval https://www.novartis.com/news/media-releases/novartis-announces-fda-approval-gilenyar-first-disease-modifying-therapy-pediatric-relapsing-multiple-sclerosis
-
this "Short Course Daratumumab " already started recruiting https://clinicaltrials.gov/ct2/history/NCT03490344?A=1&B=2&C=merged
-
Janssen changing the design of this Prostate cancer trial, adding a second arm with "JNJ-40346527 " https://clinicaltrials.gov/ct2/history/NCT03177460?A=6&B=7&C=merged
-
-
Hvor står der at de lukker og hvornår sker det?
-
God morgen.
-
I had my 5th treatment of Dara this past Friday. This followed two years of remission after the KPD therapy and Rev maintenance. The myeloma I was diagnosed with was only the Kappa light chains. They tested me Friday and my light chains were 0.75, the first time they were that low since my fourth cycle of KRD in Nov 2015. Feeling very blessed to have such a great response so quickly on this new line of therapy (DRD).
-
God morgen.:-)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind